PF-06882961
- Generic Name
- PF-06882961
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C31H30FN5O4
- CAS Number
- 2230198-02-2
- Unique Ingredient Identifier
- DN9IUI24GP
- Background
PF-06882961 is under investigation in clinical trial NCT03985293 (A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus).
- Associated Conditions
- -
- Associated Therapies
- -
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05093205
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT04889157
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT04621227
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 151
- Registration Number
- NCT04617275
- Locations
- 🇺🇸
Emerson Clinical Research Institute, Washington, District of Columbia, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸Solaris Clinical Research, Meridian, Idaho, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06882961 in Japanese Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT04552470
- Locations
- 🇯🇵
P-one clinic, Keikokai medical corporation, Hachioji, Tokyo, Japan
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
- First Posted Date
- 2019-06-13
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 412
- Registration Number
- NCT03985293
- Locations
- 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸University Clinical Investigators, Incorporated, Tustin, California, United States
🇺🇸Andres Patron D.O. P.A., Pembroke Pines, Florida, United States
4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 98
- Registration Number
- NCT03538743
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸Qps-Mra,Llc, South Miami, Florida, United States
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT03309241
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.